Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 36 for:    Acerta Pharma

Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03623373
Recruitment Status : Recruiting
First Posted : August 9, 2018
Last Update Posted : January 4, 2019
Sponsor:
Collaborator:
Acerta Pharma BV
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : November 30, 2025